Overview Dividends

(REGN) Regeneron Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075

Eye, Dermatology, Asthma, Cancer, Arthritis

Biotechnology
Market Cap in USD: 79,354m
IPO / Inception: 1991-04-02
Return 12m vs S&P 500: -5.17%

EPS (Earnings per Share)

EPS (Earnings per Share) of REGN over the last years for every Quarter: "2020-12": 9.53, "2021-03": 9.89, "2021-06": 25.8, "2021-09": 14.37, "2021-12": 21.32, "2022-03": 8.93, "2022-06": 9.77, "2022-09": 11.14, "2022-12": 12.56, "2023-03": 10.09, "2023-06": 10.24, "2023-09": 11.59, "2023-12": 11.86, "2024-03": 9.55, "2024-06": 11.56, "2024-09": 12.46, "2024-12": 12.07, "2025-03": 8.22, "2025-06": 12.89, "2025-09": 11.83,
EPS CAGR: -14.54%
EPS Trend: -13.2%
Last SUE: 1.43
Qual. Beats: 2

Revenue

Revenue of REGN over the last years for every Quarter: 2020-12: 2422.9, 2021-03: 2528.7, 2021-06: 5138.5, 2021-09: 3452.8, 2021-12: 4951.7, 2022-03: 2965.1, 2022-06: 2857.2, 2022-09: 2936.2, 2022-12: 3414.4, 2023-03: 3162.1, 2023-06: 3158.1, 2023-09: 3362.7, 2023-12: 3434.3, 2024-03: 3145, 2024-06: 3547.1, 2024-09: 3720.7, 2024-12: 3789.2, 2025-03: 3028.7, 2025-06: 3675.6, 2025-09: 3754.3,
Rev. CAGR: -7.12%
Rev. Trend: 15.0%
Last SUE: 0.91
Qual. Beats: 2

Dividends

Dividend Yield 0.45%
Yield on Cost 5y 0.73%
Yield CAGR 5y 0.00%
Payout Consistency 100.0%
Payout Ratio 7.8%
Risk via 5d forecast
Volatility 33.4%
Value at Risk 5%th 50.7%
Relative Tail Risk -7.62%
Reward TTM
Sharpe Ratio 0.35
Alpha -1.45
CAGR/Max DD 0.05
Character TTM
Hurst Exponent 0.352
Beta 0.576
Beta Downside 0.366
Drawdowns 3y
Max DD 59.69%
Mean DD 20.72%
Median DD 9.20%

Description: REGN Regeneron Pharmaceuticals December 03, 2025

Regeneron Pharmaceuticals (NASDAQ: REGN) is a U.S. biotech firm that discovers, invents, develops, manufactures, and commercializes a broad portfolio of injectable medicines across ophthalmology, immunology, oncology, cardiovascular, infectious disease, and rare-disease markets. Its flagship products include EYLEA for retinal disorders, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous-cell carcinoma, and the COVID-19 antibody cocktail REGEN-COV, among dozens of other specialty therapies.

As of FY 2023, Regeneron reported $13.3 billion in revenue, driven primarily by EYLEA (≈ $5 billion) and Dupixent (≈ $3 billion). The company reinvested roughly $3.1 billion in R&D, reflecting a pipeline of ~ 20 late-stage candidates and multiple CRISPR-gene-editing collaborations (e.g., Mammoth Biosciences). Key sector drivers that influence its outlook are the aging-population-induced demand for ophthalmic and cardiovascular drugs, the expanding market for biologics in immunology, and the industry-wide shift toward gene-editing platforms, which could materially affect future growth trajectories.

For a deeper quantitative dive, you might explore ValueRay’s analyst tools to assess Regeneron’s valuation dynamics.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (4.58b TTM) > 0 and > 6% of Revenue (6% = 854.9m TTM)
FCFTA 0.10 (>2.0%) and ΔFCFTA 1.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 95.14% (prev 113.2%; Δ -18.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.13 (>3.0%) and CFO 5.07b > Net Income 4.58b (YES >=105%, WARN >=100%)
Net Debt (199.1m) to EBITDA (5.71b) ratio: 0.03 <= 3.0 (WARN <= 3.5)
Current Ratio 4.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (107.2m) change vs 12m ago -7.75% (target <= -2.0% for YES)
Gross Margin 85.39% (prev 85.31%; Δ 0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 36.72% (prev 36.98%; Δ -0.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 123.2 (EBITDA TTM 5.71b / Interest Expense TTM 42.1m) >= 6 (WARN >= 3)

Altman Z'' 9.96

(A) 0.34 = (Total Current Assets 17.98b - Total Current Liabilities 4.43b) / Total Assets 40.17b
(B) 0.87 = Retained Earnings (Balance) 35.05b / Total Assets 40.17b
warn (B) unusual magnitude: 0.87 — check mapping/units
(C) 0.13 = EBIT TTM 5.19b / Avg Total Assets 38.81b
(D) 3.81 = Book Value of Equity 35.11b / Total Liabilities 9.21b
Total Rating: 9.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.82

1. Piotroski 7.0pt
2. FCF Yield 5.64%
3. FCF Margin 29.16%
4. Debt/Equity 0.09
5. Debt/Ebitda 0.03
6. ROIC - WACC (= 5.58)%
7. RoE 15.31%
8. Rev. Trend 15.02%
9. EPS Trend -13.24%

What is the price of REGN shares?

As of December 28, 2025, the stock is trading at USD 784.97 with a total of 320,966 shares traded.
Over the past week, the price has changed by +2.21%, over one month by +0.05%, over three months by +39.38% and over the past year by +10.14%.

Is REGN a buy, sell or hold?

Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy REGN.
  • Strong Buy: 14
  • Buy: 5
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the REGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 789.2 0.5%
Analysts Target Price 789.2 0.5%
ValueRay Target Price 794.9 1.3%

REGN Fundamental Data Overview December 27, 2025

Market Cap USD = 79.35b (79.35b USD * 1.0 USD.USD)
P/E Trailing = 17.9547
P/E Forward = 17.6678
P/S = 5.5696
P/B = 2.5455
P/EG = 1.4781
Beta = 0.368
Revenue TTM = 14.25b USD
EBIT TTM = 5.19b USD
EBITDA TTM = 5.71b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 199.1m USD (from netDebt column, last quarter)
Enterprise Value = 73.62b USD (79.35b + Debt 2.71b - CCE 8.44b)
Interest Coverage Ratio = 123.2 (Ebit TTM 5.19b / Interest Expense TTM 42.1m)
FCF Yield = 5.64% (FCF TTM 4.15b / Enterprise Value 73.62b)
FCF Margin = 29.16% (FCF TTM 4.15b / Revenue TTM 14.25b)
Net Margin = 32.13% (Net Income TTM 4.58b / Revenue TTM 14.25b)
Gross Margin = 85.39% ((Revenue TTM 14.25b - Cost of Revenue TTM 2.08b) / Revenue TTM)
Gross Margin QoQ = 86.11% (prev 85.58%)
Tobins Q-Ratio = 1.83 (Enterprise Value 73.62b / Total Assets 40.17b)
Interest Expense / Debt = 0.71% (Interest Expense 19.3m / Debt 2.71b)
Taxrate = 17.20% (303.3m / 1.76b)
NOPAT = 4.29b (EBIT 5.19b * (1 - 17.20%))
Current Ratio = 4.06 (Total Current Assets 17.98b / Total Current Liabilities 4.43b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 30.96b)
Debt / EBITDA = 0.03 (Net Debt 199.1m / EBITDA 5.71b)
Debt / FCF = 0.05 (Net Debt 199.1m / FCF TTM 4.15b)
Total Stockholder Equity = 29.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.40% (Net Income 4.58b / Total Assets 40.17b)
RoE = 15.31% (Net Income TTM 4.58b / Total Stockholder Equity 29.91b)
RoCE = 16.26% (EBIT 5.19b / Capital Employed (Equity 29.91b + L.T.Debt 1.99b))
RoIC = 13.47% (NOPAT 4.29b / Invested Capital 31.89b)
WACC = 7.89% (E(79.35b)/V(82.06b) * Re(8.14%) + D(2.71b)/V(82.06b) * Rd(0.71%) * (1-Tc(0.17)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.94%
[DCF Debug] Terminal Value 75.30% ; FCFE base≈3.84b ; Y1≈3.26b ; Y5≈2.50b
Fair Price DCF = 435.3 (DCF Value 44.96b / Shares Outstanding 103.3m; 5y FCF grow -18.28% → 3.0% )
EPS Correlation: -13.24 | EPS CAGR: -14.54% | SUE: 1.43 | # QB: 2
Revenue Correlation: 15.02 | Revenue CAGR: -7.12% | SUE: 0.91 | # QB: 2
EPS next Quarter (2026-03-31): EPS=10.43 | Chg30d=+0.166 | Revisions Net=+4 | Analysts=8
EPS next Year (2026-12-31): EPS=38.36 | Chg30d=+1.645 | Revisions Net=+2 | Growth EPS=-6.1% | Growth Revenue=+6.5%

Additional Sources for REGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle